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Rotavirus is one of the main causes of acute diarrhea and enteritis in infants. Currently,
studies are underway to assess the use of probiotics to improve rotavirus vaccine
protection. A previous work demonstrated that the probiotic strain Bifidobacterium
longum subsp. infantis CECT 7210 is able to hinder rotavirus replication both in vitro and
in vivo. The present study takes a systematic approach in order to identify the molecule
directly involved in rotavirus inhibition. Supernatant protease digestions revealed both
the proteinaceous nature of the active substance and the fact that the molecule
responsible for inhibiting rotavirus replication is released to the supernatant. Following
purification by cationic exchange chromatography, active fractions were obtained and
the functional compound was identified as an 11-amino acid peptide (MHQPHQPLPPT,
named 11-mer peptide) with a molecular mass of 1.282 KDa. The functionality of 11-
mer was verified using the synthesized peptide in Wa, Ito, and VA70 rotavirus infections
of both HT-29 and MA-104 cell lines. Finally, protease activity was detected in B. longum
subsp. infantis CECT 7210 supernatant, which releases 11-mer peptide. A preliminary
identification of the protease is also included in the study.
Keywords: B. longum subsp. infantis CECT 7210, probiotics, rotavirus, 11-mer peptide, protease
INTRODUCTION
Group A rotavirus is one of the major causes of acute gastroenteritis in infants and young
children, leading to an estimated 2 million hospitalizations per year (Parashar et al., 2006).
Despite the administration of rotavirus vaccines, rotavirus still accounts for an estimated 21.3–
39.5% of the hospital admissions for diarrheal disease in Europe (Williams et al., 2009). However,
hospitalizations of older children and adults for diarrhea have greatly decreased after the
introduction of infant rotavirus vaccination, which suggests that some rotavirus episodes were
transmitted from infants (Lopman et al., 2011). Rotaviruses are transmitted by the fecal-oral
route, inducing diarrhea due to malabsorption by the infected epithelial cells of the intestinal
mucosa (Kapikian et al., 2001) and increased intestinal motility (Istrate et al., 2014). The
mechanisms underlying diarrhea include secondary malabsorption, patchy lesions, villous atrophy,
and disruption of the tight junctions in the small intestine, altered ion channel transport due
to the secretion of neurotransmitters (Hagbom et al., 2012), NSP4 toxicity (Hodges and Gill,
2010), the activation of the enteric nervous system (Lundgren et al., 2000), and the expression
of aquaporins (Cao et al., 2014). The process is characterized by profuse diarrhea, which can
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cause severe dehydration and, in the case of non-intervention,
lead to death (Parashar et al., 2006). Several vaccines have
been developed, demonstrating different degrees of protection
against rotavirus infection (Vesikari et al., 2007; Dennehy, 2008;
Glass et al., 2014). Nevertheless, it has been reported that
despite wide coverage, the antibodies induced by vaccination
cannot totally prevent symptomatic infections of some rotavirus
genotypes (Bucardo et al., 2015). These findings imply that new
generation vaccines and complementary preventive approaches
are needed to decrease the morbidity and mortality associated
with rotavirus diarrhea (Demirjian and Levy, 2009; Glass et al.,
2014).
During the last few years, research has focused on the
potential use of probiotics as preventive agents against rotavirus.
The Food and Agriculture Organization (FAO) and the
World Health Organization (WHO) define probiotics as
“live microorganisms which when administered in adequate
amounts confer a health benefit on the host” (FAO/WHO,
2001). These microorganisms are demonstrated to be effective
in preventing several disorders such as infections, diarrhea,
and inflammatory diseases (Reid, 2008; Kotzampassi and
Giamarellos-Bourboulis, 2012). Moreover, probiotics affect the
modulation and establishment of intestinal microbiota and
enhance maturation of the innate and adaptive immune systems
among others (Kotzampassi and Giamarellos-Bourboulis, 2012).
Regarding the efficacy of these microorganisms in treating
rotavirus-related diarrhea, a number of probiotics have been
reported including Bifidobacterium longum and Lactobacillus
acidophilus strains (Lee et al., 2014) and commercial probiotic
strains such as Lactobacillus GG (Sindhu et al., 2014).
Nevertheless, most of these reports are based on the amelioration
of diarrhea symptoms but little has been published on the
identification of the mechanisms and molecules underlying
rotavirus inhibition. In this respect, current ideas regarding these
mechanisms of action include changes in gut ecology, an effect
on the gut mucosal barrier, and a modulation of the immune
response (Kotzampassi and Giamarellos-Bourboulis, 2012), each
being strain-specific (Oelschlaeger, 2010).
A previous study demonstrated that strain B. longum subsp.
infantis CECT 7210 exerts a direct in vitro effect on rotavirus
infection in HT-29 and MA-104 cell lines (Muñoz et al., 2011).
Furthermore, an in vivo effect was shown to involve both antiviral
effects and immunological enhancement, providing preliminary
protection against the rotavirus infection in a mouse model.
The strain was also characterized, demonstrating that B. longum
subsp. infantis CECT 7210 fulfills the main criteria required
for consideration as a probiotic. However, the interaction of
the probiotic with the host cell surface alone did not explain
all the mechanisms involved, since infection levels decreased
even when the probiotic was added directly to the virus,
therefore further studies must be conducted to establish the
mechanisms involved in the antiviral effect of this probiotic
strain.
Thus, the aim of this study is to identify the molecule(s)
directly responsible for the activity of strain B. longum subsp.
infantis CECT 7210 against rotavirus and to investigate the
mechanism underlying the inhibition.
MATERIALS AND METHODS
Cells and Viruses
The human colon carcinoma cell line HT-29 was grown
in Dulbecco’s modified minimal essential medium (DMEM)
supplemented with 10% (v/v) fetal bovine serum (FBS, Gibco
Invitrogen, Paisley, UK). The Rhesus monkey kidney cell line
MA-104 was grown in Eagle’s minimal essential medium (MEM)
supplemented with 10% (v/v) FBS. Human rotavirus strain Wa
(G1-P1A[8]) and simian rotavirus strain SA11 (G3-P1A[8]) were
obtained from the American Type Culture Collection. Human
rotavirus strain VA70 (G4-P1A[8]) and porcine rotavirus strain
Ito (G3-P1A[8]) were a gift from Prof. Albert Bosch (University
of Barcelona, Spain). B. longum subsp. infantis CECT 7210 is
a probiotic strain isolated from baby’s feces and identified and
characterized previously by Muñoz et al. (2011)
Rotavirus Propagation and In Vitro
Inhibition Assays
Assays were carried out as in Muñoz et al. (2011). Competition
assays were performed with rotavirus SA11, Ito, VA70 and Wa in
both HT-29 and MA-104 cell lines. In all cases, cell monolayers
were grown in 96-well plates and the tested compounds were
incubated with rotavirus followed by the infection of the cells
with this virus-compound mixture (strategy A) or the compound
was incubated with the cell cultures followed by the inoculation of
the virus (strategy B). In both cases, viral antigens were detected
by immunoperoxidase assays (Muñoz et al., 2011). Infectious
peroxidase-stained foci were counted and arithmetic means were
calculated to determine the number of foci per microscopic field,
which were compared with the number of infectious foci of
untreated virus controls to obtain the reduction percentage of
virus focus-forming units. The identified peptide was synthesized
at 90% purity (Genscript Corporation, Piscataway, NJ, USA)
and its activity was measured for both strategies at different
concentrations (1, 5, 10, and 50 µM).
Purification and Identification of the
Substance/s of Interest by Cationic
Exchange Chromatography Followed by
Reverse-Phase Chromatography
Supernatant Processing
A volume of 10 L culture of the strain B. longum subsp. infantis
CECT 7210 growing in MRS (de Man, Rogosa, and Sharpe,
CM1153, Oxoid, Basingstoke, UK) medium supplemented with
cysteine (0.05% w/v; MRSC) was obtained and centrifuged at
12,000 × g for 15 min at 4◦C. Supernatant was neutralized to
pH 6.5 with NaOH (10N), 10x concentrated by freeze-drying
and sterilized by 0.22-µm-pore-size filter (Minisart hydrophilic
syringe filter; Sartorius Stedim Biotech GmbH, Gottingen,
Germany). Concentrated supernatant was stored at −20◦C
until use.
Identification of the Nature of the Active Compound
In order to study, the nature of the substance of interest, the
freeze-dried samples were treated with lipase and proteases
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(proteinase K and pepsin). To study the effect of lipase, a
freeze-dried sample (from 25 mL supernatant) was re-suspended
in 2.4 mL phosphate buffer solution (50 mM, pH 6.9), then
0.1 mL lipase from porcine pancreas was added (50 mg/mL;
Sigma–Aldrich). The mixture was incubated at 37◦C for 2 h,
and the reaction was inactivated taking the solution to pH
4.5. Regarding pepsin, a freeze-dried sample (from 25 mL
supernatant) was re-suspended in 1.25 mL of McIlvaine buffer
50 mM pH 4.0, to which 0.109 mL of a pepsin solution was added
(50 mg/mL; Sigma–Aldrich, St. Louis, MO, USA). This mixture
was incubated at 37◦C for 2 h, and the reaction was inactivated
taking the solution to pH 6.5 in a final volume of 2.5 mL.
In the case of proteinase K, freeze-dried sample (from 25 mL
supernatant) was re-suspended in 2.4 mL of phosphate buffer
50 mM pH 6.5, to which 0.1 mL of a proteinase K solution was
added (50 mg/mL; Sigma–Aldrich). This mixture was incubated
at 37◦C for 2 h, and then proteinase K was inactivated by
incubation at 100◦C for 15 min. Analysis of the inhibition of
proliferation of rotavirus SA11 was performed in all processed
supernatants.
The negative controls included in these tests were supernatant
of culture medium MRSC without inoculation (C1) and the same
supernatant incubated for 2 h at 37◦C (QC3). Control with non-
inactivated proteinase K supernatant could not be tested due to
post-incubation cell lysis. As a negative control of inhibition, a
non-fermented freeze-dried sample was used (C1). As positive
control of infection, a solution containing cells and viruses was
used.
Purification and Identification of the Substance
Active against Rotavirus
Purification was performed following Chenoll et al. (2011).
Briefly, the supernatant was added to sodium phosphate buffer
(20 mM, pH 5.8) and then applied to a cationic exchange column
(HiPrep 16/10 SP FF, GE Healthcare, Amersham Biosciences
AB, Sweden) by means of a chromatography system (ÄKTA
Explorer, Amersham Pharmacia Biotech). All those proteins
of cationic nature adsorbed were then eluted with sodium
phosphate buffer (20 mM, pH 5.8) and equilibrated with NaCl
1M without gradient. The proteins were eluted simultaneously
in a few fractions in minimal volume (10 mL). Each collected
fraction was subjected to an ultrafiltration process using 5,000 Da
filters (Extreme Amicon, Millipore, Billerica, MA, USA) followed
by another stage of reverse phase chromatography with a
RESOURCE RPC 3 mL column (GE Healthcare). An aliquot of
these fractions was taken to dryness to eliminate the dissolvent
and re-suspended in a volume of MEM buffer (Sigma–Aldrich)
just before performing in vitro inhibition assays. In total, 28
fractions were selected for rotavirus inhibition assays (strategy
B) with SA11 virus in MA-104 cell line as explained above. The
fractions that gave a positive inhibition result were analyzed
by MALDI-TOF peptide mass fingerprinting at the “Centro
Nacional de Investigaciones Cardiovasculares” (CNIC, Madrid,
Spain), to determine the molecular weight(s) of the peptide(s)
present in each fraction. Sequences obtained were compared
against the database of proteins/peptides by means of the BLAST
online tool.
Purification and Identification of the
Protease
Supernatant Processing
A volume of 1 L culture of strain B. longum subsp. infantis
CECT 7210 in MRSC medium was obtained and centrifuged
at 12,000 × g for 15 min under refrigerated conditions.
Proteins were precipitated by the addition of ammonium sulfate
(80% saturation) and collected by centrifugation (30 min,
12,000 × g). Pellet was resuspended in Tris-HCl buffer (Tris-
HCl 20 mM, pH 8.5), dialyzed with a 10 KDa membrane
at 4◦C and applied to an anionic exchange column (HiPrep
16/10 Q XL, GE Healthcare) by means of a chromatographic
system (ÄKTA Explorer). Anionic proteins were eluted with
buffer Tris-HCl (20mM, pH 8.5, CaCl2 5 mM) using a
gradient of NaCl from 0 to 1 M. As an indicator of the
purification process, samples were monitored at 280 nm
throughout elution and protease activity measured with BSA
as a substrate following Bradford (1976). Protease-positive
fractions were then concentrated by 10 KDa ultrafiltration
(Millipore), diluted with distilled water and applied to gel
filtration chromatography (1% column volume) with a HiLoad
Superdex 75 prep grade column (GE Healthcare Europe GmbH,
Barcelona, Spain) with fractionation in a range of 3,000–
70,000 Da. Sample was monitored with absorbance at 280 nm,
and fractions with proteins were collected, desalted by PD10
columns (GE Healthcare Life Sciences) and concentrated by
10 KDa ultrafiltration. A volume of 30 µL of protease-positive
fraction was electrophoresed on a 12.5% polyacrylamide SDS-
PAGE gel. Gel was stained with silver nitrate and a 209–
7.1 KDa commercial molecular weight marker (SDS-PAGE
Standards, Broad Range) was used. The single band was separated
and analyzed by MALDI-TOF peptide mass fingerprinting
at CNIC, to determine the molecular weight and sequence
of the protein. Sequence obtained was compared against the
database of proteins/peptides by means of the BLAST online
tool.
Evaluation of 11-mer Production from β-Casein Using
the Purified Protease
In order to evaluate whether the purified protease hydrolyzes
β-casein protein to obtain 11-mer peptide, an enzymatic
activity assay was performed with β-casein as substrate and
purified protease from CECT 7210 supernatant as enzyme.
The hydrolysis was carried out in a solution containing 15 ml
of protease-purified fraction (0.04 U), 30 mL of 2% β-casein
solution (BioUltra, Sigma–Aldrich) and 105 mL phosphate
citrate buffer (50 mM pH 6.4). After 48 h hydrolysis at 50◦C,
samples were boiled for 10 min and peptides formation was
analyzed by HPLC. Evaluation of 11-mer formation and β-casein
degradation was conducted on a HPLC (Waters 2695) with
photodiode array detector (Waters 2996) and C18 column
(Sunfire Waters C18 5 mm 4.6∗150 mm). Eluents were water
(MilliQ quality; A) and acetonitrile (90% v/v; B), both with
TFA 0.1% (v/v). Chromatographic conditions are summarized in
Table 1.
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TABLE 1 | HPLC chromatographic conditions used to quantify peptide
11-mer.
Time (min) % Buffer A % Buffer B
– 100 0
40 50 50
42 0 100
50 0 100
60 100 0
Characterization of the Purified Protease
Carbon Sources
Protease activity was assayed in supernatants of strain CECT 7210
grown in MRSC media containing glucose, lactose or maltose as
sole carbon source, respectively (all of them at 20 g/L). Protease
activity was measured in supernatants after 17 h of growth
and centrifuged at 12,000 × g for 15 min under refrigerated
conditions. BSA degradation (1% w/v, citrate-phosphate buffer
50 mM, pH 6.4) was measured at different incubation times
(1 h, 3 h and 5 h) both with the supernatants and with 3 KDa
concentrated fractions. Using the supernatants and the 3 KDa
concentrated fractions, enzymatic reactions were performed with
β-casein as substrate. Assays were performed as described above
and β-casein degradation and 11-mer formation were monitored
by HPLC.
Optimum pH
The protease assay was performed at different pH values with
purified protease. A β-casein solution (2% w/v) was incubated
with purified protease at 50◦C (optimum temperature) for 72 h.
The hydrolysis reaction was carried out in a solution with purified
protease (10 mL), β-casein solution (2% w/v; 20 mL) and PBS
buffer (70 mL), at pH 4, 6, 7, 8, and 10. After incubation, samples
were boiled for 10 min to stop the reaction, filtered through
a Millipore 0.45 µm pore-size filter and 11-mer peptide was
analyzed by HPLC.
Optimum Temperature
The protease assay was performed with purified protease at
different temperatures. The β-casein degradation assay was
carried out as above, during 72 h, at pH 6.4 and at temperatures
of 35, 40, 50, and 60◦C. As in the case of pH studies, the amount
of 11-mer peptide was analyzed by HPLC.
Influence of Zinc, Potassium, and Calcium
The influence of zinc, potassium, and calcium on the purified
protease activity was studied. As above, the assay was carried
out with β-casein (2% w/v) as substrate and 70 µL citrate-
phosphate buffer (pH 6.4, 50 mM). Incubation conditions were
50◦C (optimum temperature) for 72 h. Minerals were added
separately at a final concentration of 10 mM. After incubation,
samples were boiled and 0.45 µm pore-size filtered, and 11-
mer was analyzed by HPLC. A control was included without the
addition of any mineral.
Statistical Analysis
In all cases, results obtained were analyzed using GraphPad Prism
4 software (GraphPad software, La Jolla, CA, USA). Data were
subjected to one-way analysis of variance (ANOVA). The Tukey’s
multiple comparison test was used for comparison of means.
RESULTS
Purification and Identification of the
Substance of Interest by Cationic
Exchange Followed by Reverse-Phase
Chromatography
Identification of the Nature of the Active Compound
In order to determine the nature of the active compound
responsible for inhibition of rotavirus, the freeze-dried samples
were treated with proteinase K, pepsin and lipases. Non-treated
CECT 7210 supernatant significantly decreased infection via
either strategy A or B, by 51.6 and 83%, respectively (Table 2).
Analysis of rotavirus SA11 proliferation for the aliquots processed
by lipases showed no changes in supernatant rotavirus inhibition
values (data not shown). Supernatant treated with proteases
showed no inhibition of rotavirus infection via either strategy A
or B (Table 2) and confirmed the proteinaceous nature of the
active compound.
Purification and Identification of the Active
Substance against Rotavirus
The strategy used to identify the active substance against
rotavirus started with its purification from the CECT 7210 active
supernatant. To do this, a total of 28 fractions of reverse phase
were selected for rotavirus inhibition assays (strategy B). Of these,
only six fractions rendered a significant reduction in infected
foci and were selected for further investigation. The selected
fractions are summarized in Table 3. All the fractions that proved
positive for inhibition were analyzed by MALDI-TOF peptide
mass fingerprinting to determine the molecular weights of the
peptide/s present in each fraction (results of each fraction are not
shown). Analyzing all the spectra, the only common signal in all
TABLE 2 | Assay for in vitro activity against human rotavirus SA11 in
MA-104 cell line in supernatants obtained with the growth of B. longum
subsp. infantis CECT 7210, and treated.
Assays % Focus of infection ± SD
Strategy A Strategy B
Pepsin treated supernatant of CECT7210 134.6 ± 26.7 117.9 ± 26.8
Proteinase K treated supernatant of CECT7210 117.9 ± 33.4 101.8 ± 7.6
Untreated CECT 7210 supernatant 48.4 ± 30.7a 17.0 ± 4.1b
Assay positive control 100.0 ± 32.2 100.0 ± 33.3
Negative control QC3 121.7 ± 7.14 96.4 ± 16.3
Negative control C1 100.0 ± 16.1 100.0 ± 33.3
Results are the average of three different experiments and are expressed as
percentage of infectious foci. SD, standard deviation; aP-value < 0.05; bP-
value < 0.01.
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TABLE 3 | Inhibition of rotavirus SA11 infection in MA-104 cell line by
selected reverse phase fractions following strategy B.
Sample Fraction of cationic exchange % Focus of infection ± SD
2/13 2 54.4 ± 12.1a
3/9 3 56.9 ± 29.3a
3/10 23.6 ± 16.6b
4/8 4 25.8 ± 8.9b
4/11 27.9 ± 8.6b
4/27 70.5 ± 18.7
Control 100.0 ± 10.9
Results are the average of at least two independent experiments. SD, standard
deviation; aP-value < 0.05; bP-value < 0.001.
the selected fractions corresponded to a peptide with a molecular
weight of 1,282.63 Da. To identify the molecule with potential
activity against rotavirus, the signal was identified by de novo
sequencing, and the result was a peptide of 11-amino acids
whose sequence was MHQPHQPLPPT (named 11-mer peptide)
and whose molecular mass was 1282.63 Da (Figure 1). This
sequence was checked against the data base of proteins/peptides
by means of the BLAST online tool1, and was identified as a part
of the cow milk β-casein, corresponding to amino acids sequence
(position 158–169; Bos taurus β-casein, GenBank accession no.
AAA30431.1, gi: 162805).
1http://blast.ncbi.nlm.nih.gov/Blast.cgi
Analysis of the Inhibition of Human Rotavirus
Proliferation by 11-mer Peptide
In order to determine whether 11-mer peptide was responsible
for rotavirus inhibition, assays with human rotavirus Wa, Ito,
and VA70 were performed in MA-104 and HT-29 cell lines with
the synthesized peptide, and following both strategy A (tested
compounds were incubated with rotavirus prior to cells infection;
Figure 2) and B (cells were incubated with tested compounds
prior to cells infection; Figure 3). Results were different in the
case of each virus and cell line. In general, inhibition percentages
were higher in assays performed in MA-104 cell line. Taking
into account peptide concentration, inhibition results reached a
plateau at lower concentrations (1 µM) and did not improve with
higher peptide amounts. This result may be due to the potential
formation of 11-mer peptide aggregates at higher concentrations,
which leads to a loss of functionality depending on virus and cell
line. For strategy A, no inhibition was obtained in VA70 assays.
In the case of Wa virus assays, the highest inhibition percentage
was 28.4% foci reduction at 1 µM 11-mer concentration (p-
value < 0.001). In the case of Ito virus, foci reduction ranged
from 33.3 and 53.7% in MA-104 cell line and from 11.6 and
26.8% in HT-29 cells. Following strategy B, Wa, Ito, and VA70
virus infections were inhibited for MA-104 cell line assays, the
highest result being a 39.3% foci reduction at 5 µM 11-mer
concentration (Wa virus). In HT-29 cells, no inhibition was
obtained with Wa virus, and inhibition rendered its maximum
for VA70 virus at 50 µM 11-mer concentration (31.8% foci
reduction, p-value < 0.01).
FIGURE 1 | MALDI mass spectrum of the common peptide among functional fractions obtained following purification by cationic exchange
chromatography.
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FIGURE 2 | Percentage of focus reduction in human rotavirus infection by strategy A, in which 11-mer peptide was incubated with rotavirus followed
by the infection of the cells with this virus-compound mixture. Black bars correspond to MA-104 cell line and gray bars to HT-29 cell line. (A) Wa virus assays;
(B) Ito virus assays. No inhibition was obtained for virus Va70. Data are the average of at least two independent experiments. Error bars represent the standard
errors for replicates. ∗P-value < 0.05; ∗∗P-value < 0.01.
Purification and Identification of the
Protease
As human rotavirus proliferation is thought to be inhibited by
the 11-mer peptide (found in cow milk β-casein), we evaluated
a hypothetical mechanism whereby the peptide is released by
a potential supernatant protease activity, which hydrolyses the
casein present in MRS broth. To check this hypothesis, a strategy
was adopted to purify and identify the potential enzyme. First
of all, supernatant was chromatographically purified and the
final protease-positive fraction was electrophoresed. The single
47 KDa band present in the SDS-PAGE gel was separated
and analyzed by MALDI-TOF peptide mass fingerprinting.
The band was identified as “MalE-type ABC sugar transport
system periplasmic component,” being the highest homology
with sequence gi| 189440352 (MalE-type ABC sugar transport
system periplasmic component from B. longum DJO10A), which
has a molecular weight of 47.155 KDa. In order to evaluate the
formation of 11-mer peptide from β-casein by the activity of
the purified protease, a hydrolysis assay was performed using
the purified protease as enzyme and β-casein as substrate. After
48 h of hydrolysis, peptide quantification by HPLC showed an
efficiency of 28± 1 µg of 11-mer peptide/mL.
Characterization of the Purified Protease
The purified protease was characterized in terms of carbon
source, pH, temperature, and cofactors. Protease activity from
B. longum CECT 7210 supernatants of media containing glucose,
lactose, and maltose as sole carbon source is shown in Table 4.
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FIGURE 3 | Percentage of focus reduction in human rotavirus infection by strategy B, in which 11-mer peptide was incubated with the cell cultures
followed by the inoculation of the virus. Black bars correspond to MA-104 cell line and gray bars to HT-29 cell line. (A) Wa virus assays; (B) Ito virus assays;
(C) VA70 virus assays. Data are the average of at least two independent experiments. Error bars represent the standard errors for replicates. ∗P-value < 0.01;
∗∗P-value < 0.001.
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TABLE 4 | Protease activity and 11-mer production of both supernatants and concentrated fractions (higher than 3 KDa) in supernatants obtained with
the growth of B. longum subsp. infantis CECT 7210 in the presence of different carbohydrates, at different times of incubation.
Protease activity ± SD (mUI/mL) 11-mer production ± SD (µg/mL)
Time of incubation Glucose Lactose Maltose Glucose Lactose Maltose
Supernatant 1 h 1.67 ± 1.41 2.67 ± 1.89a 15.33 ± 0.94a n.t. n.t. n.t.
3 h 1.11 ± 1.57 12.22 ± 3.14b 36.11 ± 2.36a n.t. n.t. n.t.
5 h 5.33 ± 0.94 9.00 ± 0.47b 30.00 ± 0.94a 47 ± 4 65 ± 10 90 ± 6b
>3 KDa fraction 1 h 81.67 ± 11.36 283.33 ± 47.14b 973.33 ± 202.70a n.t. n.t. n.t.
2 h 153.33 ± 16.50 508.33 ± 9.43a 1005.83 ± 48.31c 39 ± 7 73 ± 13 110 ± 45
Results are the average of at least two different experiments. SD, standard deviation; n.t., not tested; aP-value < 0.01; bP-value < 0.05; cP-value < 0.001.
In all cases, significant higher activity was found in supernatants
in which the probiotic strain B. longum CECT 7210 was grown
in the presence of maltose. The supernatants rendered the
highest value at 3 h of incubation in media with maltose,
with an activity of 36.11 mU/mL (p-value < 0.01). Regarding
the purified fraction, activity values were around 28 times
higher, with a maximum of 1005.83 mU/mL of activity, at 2 h
of incubation (p-value < 0.001). Table 4 summarizes peptide
quantification obtained when supernatants and concentrated
fractions were incubated with β-casein as substrate. Results
ranged from 39 to 110 µg of 11-mer peptide/mL, with the
highest value corresponding to supernatants and fractions
obtained from the growth of probiotic CECT 7210 with
maltose as sole carbon source (90 and 110 µg peptide/mL,
respectively).
Results regarding the effect of pH and temperature in 11-mer
production from the purified protease are summarized in Table 5.
The maximum 11-mer peptide concentration was 21 µg/mL.
This value was obtained at pH 7–8. No significant differences
were obtained at pH 4–10. Regarding the optimum reaction
temperature, values obtained ranged from 20 to 22 µg of 11-mer
peptide/mL, but no significant differences were found. Maximum
concentration of 11-mer peptide was obtained at 50◦C and no
activity was found at 60◦C.
In order to characterize the purified protease thoroughly,
we analyzed the influence of zinc, potassium, and calcium as
cofactors on 11-mer formation. Results are shown in Table 6,
and ranged from 11 to 21 µg 11-mer peptide/mL, with the
highest value corresponding to the assay without mineral
addition.
TABLE 5 | Effect of pH and temperature in 11-mer production by using
protease-extract as enzyme and β-casein as substrate.
11-mer (µg/mL) ± SD
pH Temperature
pH 4 19 ± 3 30◦C 21 ± 3
pH 6 20 ± 4 35◦C 20 ± 4
pH 7 21 ± 3 40◦C 22 ± 5
pH 8 21 ± 4 50◦C 21 ± 2
pH 10 20 ± 3 60◦C n.d.
Data are the average of at least two independent experiments. n.d., not detected.
TABLE 6 | Evaluation of the effects of zinc, calcium, and potassium
addition on the production of 11-mer peptide from β-casein.
Ions % 11-mer peptide production ± SD
Control 100
Zn 57.65 ± 1.88b
Ca 82.54 ± 4.53a
K 82.63 ± 6.03a
Control has no mineral addition. Data are the average of at least two independent
experiments. SD, standard deviation; aP-value < 0.01; bP-value < 0.001.
DISCUSSION
Recent clinical trials have demonstrated that some probiotic
strains are able to ameliorate acute rotaviral diarrhea (Grandy
et al., 2010; Lee et al., 2014). It is assumed that gut
microbiota balance, the enhancement of mucosal barrier and the
modulation of the immune response afford protection against
rotavirus diarrhea (Kotzampassi and Giamarellos-Bourboulis,
2012). However, few studies have investigated the mechanisms
underlying the protective effect of probiotics against rotavirus.
A previous work demonstrated the direct effect of strain
B. longum subsp. infantis CECT 7210 against rotavirus replication
(Muñoz et al., 2011). Likewise, Lee et al. (2014) found that
B. longum (IBG) and L. acidophilus (LA) strongly inhibited
rotavirus infection using Vero cell line, but did not identify
the mechanism further. In another study, Maragkoudakis et al.
(2010) investigated the induction of NO- and H2O2 reactive
oxygen species (ROS) released by cell lines co-incubated with
lactic acid bacteria, and results were strain and cell line specific.
Other data report that probiotics can block viral attachment by
competitive inhibition if they are able to bind viral receptors at
the surface of intestinal cells (Colbère-Garapin et al., 2007). In our
study, a systematic approach was taken to identify the molecules
directly involved in rotavirus inhibition.
First of all, to determine the nature of the substance of
interest, supernatants with and without enzymatic treatment
were analyzed for functionality. In these assays, the high
percentage of inhibition of the non-treated cell-free supernatants
suggested that part of the activity of CECT 7210 strain
against rotavirus was not directly exerted by cells, and that
the molecule responsible for direct rotavirus inhibition was
released to the supernatant, as previously hypothesized for other
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probiotic strains (Botic´ et al., 2007). In assays performed to
identify the nature of the functional compounds, treatment with
different proteases eliminated inhibition capacity, confirming
the proteinaceous nature of the substance responsible for
inhibiting rotavirus infection. Similar assays were applied with
lipases but inhibition capacity was not reduced (data not
shown), refuting the potential lipidic nature of the substance of
interest.
The direct effect of different compounds such as polyphenols
(Kwon et al., 2010) or theaflavins (Clark et al., 1998) against
rotavirus have been reported previously; however, the role played
by molecules of a proteinaceous nature against rotavirus has been
poorly described. In the literature, the most frequently reported
protein is lactoferrin, which confers at least part of the antiviral
properties of breast milk (van der Strate et al., 2001), and prevents
the adsorption of rotavirus to the target cell due to its capacity to
bind virus particles (Superti et al., 1997).
Once we had confirmed the proteinaceous nature of the
substance acting against rotavirus, we went on to identify the
active compound. We performed a supernatant purification
strategy based on cationic exchange chromatography. This
strategy had been carried out successfully to purify a probiotic
antibacterial compound (Chenoll et al., 2011). Following this
strategy, 28 fractions with cationic nature were obtained. Based
on the inhibition of rotavirus infection, only six fractions were
positive and thus selected for MALDI-TOF further analysis.
Their spectra pointed to one functional compound, the 11-
amino acid peptide MHQPHQPLPPT (11-mer), common in
all the positive fractions. This peptide is part of cow milk
β-casein and has a molecular mass of 1.28263 KDa. In order
to verify the functionality of the 11-mer peptide, inhibition
assays were run with the synthesized peptide in Wa, Ito, and
VA70 rotavirus using both HT-29 and MA-104 cell lines. The
results were similar to those previously published with the
probiotic B. longum CECT 7210 (Muñoz et al., 2011), reaching
a maximum of 56% of infectious foci inhibition, and clearly
confirming peptide 11-mer as being responsible for rotavirus
inhibition. Reports on the direct activity of peptides against
rotavirus are very scarce. Ijaz et al. (1998) found that a synthetic
peptide from VP4 directly inhibited rotavirus. Their study
hypothesized that VP4-peptide blocks the receptor sites on
the host cells. In other studies, Kvistgaard et al. (2004) and
Bojsen et al. (2007) found that some bovine macromolecular
whey proteins may exert in vitro and in vivo inhibitory activity
against rotavirus, the major component being bovine IgG.
Regarding lactoferrin, few peptides have been reported. Superti
et al. (1997) used different peptides coming from artificially
hydrolyzed lactoferrin to demonstrate that some peptides are
able to interfere with different stages in virus replication, and
the importance of specific recognition events. Regarding casein
as the source of antiviral activity, previous work in bovine
milk demonstrated the antiviral activity of κ-casein against
human rotavirus and concluded that the inhibitory mechanism
of bovine κ-casein against human rotavirus involves direct
binding to viral particles via glycan residues (Inagaki et al.,
2014). In our case, the 11-mer peptide does not contain glycan
residues, and furthermore, its antiviral activity is conserved
with synthesized peptide (with no glycan residues). Therefore,
another mechanism must be involved in its activity against
rotavirus. The facts that the peptide was effective in assays
carried out with both strategies (A and B), and that we found
different sensitivities depending on the virus and cell line,
strongly suggest a two-way effect, in which the interaction
of the peptide with both the mammalian cell surface and
directly with the virus, must play a role in the inhibition
mechanism, as hypothesized previously (Muñoz et al., 2011).
Moreover, positive results were obtained even at low peptide
concentrations (1 µM), showing the peptide exerts a strong
activity.
To identify the source of the 11-mer peptide, the analysis
of all the experimental data lead us to hypothesize a secondary
origin of the peptide, derived from the preliminary digestion
of casein present in the commercial MRS growth medium
used. A protease secreted by the probiotic strain B. longum
subsp. infantis CECT 7210 may release 11-mer peptide by
hydrolyzing the casein present in the culture. A mechanism
by which functional molecules are released from casein was
previously described by Janer et al. (2005) in B. animalis subsp.
lactis species. These authors described a zinc metallopeptidase
(PepO) able to hydrolyze αs1-casein (f1-23), which was suggested
to play a role in the increased growth of B. animalis subsp.
lactis in milk. Accordingly, we performed the purification
and identification of the protease responsible for 11-mer
production. To obtain the protease, we applied a strategy
based on fractionation by anionic chromatography. Following
this protocol, a protease-positive anionic extract was obtained,
and a SDS-gel band confirmed a unique band. MALDI-TOF
peptide mass fingerprinting analysis identified the purified
protease as “MalE-type ABC sugar transport system periplasmic
component.” This is a periplasmic binding protein, part of
the Maltose ABC sugar transport system, which is involved
in the transport of maltose and maltodextrins. Although
preliminary studies with this component were performed in
Salmonella enterica subsp. enterica serovar Typhimurium and
Escherichia coli (reviewed in Ehrmann et al., 1998), it has been
found in other bacteria, including bifidobacteria (Balac_0483
in assembly NC_012814.1 from B. animalis subsp. lactis Bl-
04, BLD_1008 in assembly ACD98454.1 from B. longum
DJO10A). With the data obtained by the whole genome
sequencing of B. longum CECT 7210 strain (Chenoll et al.,
2015; genome reference LN824140), the protein has been
identified in its genome, with a molecular weight of 46.89 KDa,
confirming that the protein is produced by this probiotic
strain. Once identified, the MalE-type ABC sugar transport
system periplasmic component was characterized in terms of
its protease activity. The results obtained in inhibition studies
with glucose, lactose, and maltose supernatants showed the
highest activity when the probiotic was grown in maltose
as the only carbon source. Moreover, maltose-grown purified
fractions were around 28 times higher, with a maximum of
1000 mU mL−1 of activity. These results, together with the
quantification of 11-mer peptide when these supernatants and
fractions were incubated with β-casein, confirmed that protease
activity is enhanced when maltose is the sole carbon source. This
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supports the identification of the MalE-type ABC sugar transport
system periplasmic component as the molecule responsible
for this protease activity. Although protease activity in MalE
has not been described previously, our data point to a
mechanism whereby the formation of the 11-mer peptide
from β-casein is caused by the direct action of the purified
protein, with an efficiency of 28 ± 1 µg/mL of reaction.
Finally, optimum pH and temperature for purified protease
activity have been established and the influence of zinc,
potassium, and calcium as cofactors on 11-mer production
discarded.
To our knowledge, this is the first report of a mechanism
by which a probiotic produces a functional molecule exerting a
direct activity against rotavirus. This mode of action supports
the potential use of strain CECT 7210 in dairy infant formulas,
in which functional peptide 11-mer would be produced by the
probiotic from cow milk β-casein.
In summary, the results presented here are the first to identify
a naturally produced peptide, the 11-mer (MHQPHQPLPPT),
as the molecule directly responsible for rotavirus inhibition
demonstrated by the probiotic B. longum subsp. infantis CECT
7210. The data reported here point to a mechanism based
on the MalE-type ABC sugar transport system periplasmic
component, which is able to exert a protease activity and
to hydrolyze β-casein to produce the functional 11-mer
peptide.
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